Literature DB >> 16181709

Molecular and cellular mechanisms of protective immunity to coccidioidomycosis.

Theo N Kirkland1, Eyal Raz, Sandip K Datta.   

Abstract

Coccidioides immitis is endemic in the soil of the desert Southwest. It causes a respiratory infection that is usually mild, but can last months and may disseminate beyond the lung. Disseminated infections can be fatal or require life-long therapy. Development of an effective vaccine may be a successful method of preventing serious disease. In this paper, we show that immunostimulatory-oligodeoxynucleotides (ISS-ODN) are an effective adjuvant for a recombinant coccidioidal protein known as antigen 2/proline rich antigen. Protective immunity induced by this ISS-ODN-based vaccine requires IL-12, interferon-gamma and MHC Class II-restricted T-cells. Cytotoxic CD8 T-cells are not required. This study elucidates the mechanisms needed to elicit successful immunity against coccidioidomycosis, and holds promise for development of an effective coccidioidal vaccine against coccidioidomycosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181709     DOI: 10.1016/j.vaccine.2005.07.092

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease.

Authors:  George R Thompson; David A Stevens; Karl V Clemons; Josh Fierer; Royce H Johnson; Jane Sykes; George Rutherford; Michael Peterson; John W Taylor; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2014-10-16       Impact factor: 2.574

2.  Multivalent recombinant protein vaccine against coccidioidomycosis.

Authors:  Eric J Tarcha; Venkatesha Basrur; Chiung-Yu Hung; Malcolm J Gardner; Garry T Cole
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

Review 3.  Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Authors:  Chinh Nguyen; Bridget Marie Barker; Susan Hoover; David E Nix; Neil M Ampel; Jeffrey A Frelinger; Marc J Orbach; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

Review 4.  Advances in combating fungal diseases: vaccines on the threshold.

Authors:  Jim E Cutler; George S Deepe; Bruce S Klein
Journal:  Nat Rev Microbiol       Date:  2006-12-11       Impact factor: 60.633

Review 5.  Fungal cell wall vaccines: an update.

Authors:  John E Edwards
Journal:  J Med Microbiol       Date:  2012-01-19       Impact factor: 2.472

6.  The role of reactive oxygen intermediates in experimental coccidioidomycois in mice.

Authors:  David A Margolis; Suganya Viriyakosol; Joshua Fierer; Theo N Kirkland
Journal:  BMC Microbiol       Date:  2011-04-11       Impact factor: 3.605

Review 7.  The public health impact of coccidioidomycosis in Arizona and California.

Authors:  Richard F Hector; George W Rutherford; Clarisse A Tsang; Laura M Erhart; Orion McCotter; Shoana M Anderson; Kenneth Komatsu; Farzaneh Tabnak; Duc J Vugia; Ying Yang; John N Galgiani
Journal:  Int J Environ Res Public Health       Date:  2011-04-15       Impact factor: 3.390

Review 8.  The Quest for a Vaccine Against Coccidioidomycosis: A Neglected Disease of the Americas.

Authors:  Theo N Kirkland
Journal:  J Fungi (Basel)       Date:  2016-12-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.